Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalMEX:BMRN 80 Return-on-Tangible-Equity is 7.35% as of Mar. 2026, which is 453% above its 10-year median of 1.33. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,506.12 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,199 Biotechnology companies, BioMarin Pharmaceutical ranks better than 81.65% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioMarin Pharmaceutical's annualized net income for the quarter that ended in Mar. 2026 was MXN7,612 Mil. BioMarin Pharmaceutical's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN103,505 Mil. Therefore, BioMarin Pharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 7.35%.
The historical rank and industry rank for BioMarin Pharmaceutical's Return-on-Tangible-Equity or its related term are showing as below:
MEX:BMRN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -35.65 Med: 1.33 Max: 28.65
Current: 4.79
During the past 13 years, BioMarin Pharmaceutical's highest Return-on-Tangible-Equity was 28.65%. The lowest was -35.65%. And the median was 1.33%.
MEX:BMRN's Return-on-Tangible-Equity is ranked better than 81.65% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs MEX:BMRN: 4.79
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BioMarin Pharmaceutical Return-on-Tangible-Equity Related Terms
BioMarin Pharmaceutical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for BioMarin Pharmaceutical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BMRN vs CYTK, ARWR, TECH: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.35% mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Return-on-Tangible-Equity of 7.35% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioMarin Pharmaceutical and its competitors. This is 453% above median its historical median of 1.33. According to the industry distribution chart, BioMarin Pharmaceutical ranks #220 out of 1199 companies in the Biotechnology industry, placing it in the top 18.3%.
Is BioMarin Pharmaceutical's Return-on-Tangible-Equity too high?
BioMarin Pharmaceutical's current Return-on-Tangible-Equity of 7.35% is 453% above median its 10-year median of 1.33. Based on the distribution chart, BioMarin Pharmaceutical ranks #220 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Return-on-Tangible-Equity compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #220 out of 1199 companies for Return-on-Tangible-Equity. This places BioMarin Pharmaceutical in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Return-on-Tangible-Equity is 7.35%, which is 453% above median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,506.12, compared to a current price of MXN959.00 — trading 36.3% below its estimated fair value. The current Return-on-Tangible-Equity is 7.35%, which is 453% above median its 10-year median of 1.33. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Return-on-Tangible-Equity is 7.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 36.3% below its estimated GF Value™ of MXN1,506.12.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
Return-on-Tangible-Equity: 7.35% (453% above median its 10-year median of 1.33)
GF Value™: MXN1,506.12 vs. price of MXN959.00 (36.3% below fair value)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
